PROMOMED biopharmaceutical Company has gathered leading analysts, journalists and representatives of the investment community at the annual Investor Day in Moscow.
CEO Alexander Yefremov noted that in 2025 PROMOMED became the leader in revenue growth among all issuers of the Moscow Stock Exchange. The market of drugs for the treatment of obesity remained the driver of growth last year. Since the company's IPO, it has doubled to 46 billion rubles. The leadership in this segment is confidently held by Tirzetta®, the best–selling and most successful new product in Russia.

The topic of innovation was continued by Kira Zaslavskaya, Director of New Products at PROMOMED. "In 2026, we launched a series of phase studies that examine efficacy and safety rather than the bioequivalence of drugs. A breakthrough technology of bispecific conjugate antibodies, an anti-HIV drug with the ability to reduce intake to several times a year, and a solution against autoimmune diseases based on janus kinase inhibitors are at the preclinical study stage. All these studies will enter the clinical stage in the near future. We have developed platform solutions that allow us to quickly bring new drugs to the market. We actively use artificial intelligence technologies. Thanks to such solutions, it was possible to obtain a registration certificate 1.5 years earlier," Kira Zaslavskaya shared.

The data of the PROMMED experts was also confirmed by the analysts of the DSM Group. Sergey Shkuliak stressed that the pharmaceutical market has doubled in the last 10 years. Among the features, the expert noted the growth in tablets and ampoules. Consumers are opting for larger packages. Generics occupy a large part of the market in both packages and tablets.

The most dynamic growth is observed in the group of GLP-1 drugs. In 2025, the growth was 177%.

Timofey Solovyov, Director of Economics and Finance at PROMMED, presented an updated revenue and profitability forecast for the next few years, confirming the high growth rates of operational efficiency.

The conference participants highly appreciated the event, noting the high degree of openness and informative content of the materials presented. The next Investor Day is scheduled to be held next year.